CT REMED

Clinical Trial REMED

COVID-19 is still a significant challenge for medical research, exploring new drugs or possible optimizing the use of existing drugs. One way to use an existing medicine is to use the corticosteroid dexamethasone. REMED clinical trial aims to test the hypothesis that administration of dexamethasone 20 mg daily is more effective in the context of COVID-19 than a daily dose of dexamethasone 6 mg in adult patients with moderate or severe ARDS. This multicenter study initiator is the University Hospital Brno – Department of Anaesthesiology, Resuscitation and Intensive Care Medicine, which in cooperation with LRI CZECRIN carries out the study in 10 centres of the Czech Republic with 300 patients.